Your browser is no longer supported. Please, upgrade your browser.
Aravive, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own4.60% Shs Outstand18.07M Perf Week-7.13%
Market Cap103.02M Forward P/E- EPS next Y-1.96 Insider Trans0.00% Shs Float9.59M Perf Month6.50%
Income-27.80M PEG- EPS next Q-0.40 Inst Own32.00% Short Float15.54% Perf Quarter-33.42%
Sales5.90M P/S17.46 EPS this Y-23.00% Inst Trans6.06% Short Ratio7.28 Perf Half Y-18.46%
Book/sh3.80 P/B1.34 EPS next Y-7.70% ROA-38.60% Target Price- Perf Year-59.07%
Cash/sh3.88 P/C1.31 EPS next 5Y- ROE-49.20% 52W Range4.27 - 14.94 Perf YTD-9.93%
Dividend- P/FCF- EPS past 5Y35.30% ROI- 52W High-64.87% Beta3.07
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin- 52W Low22.92% ATR0.31
Employees17 Current Ratio9.00 Sales Q/Q- Oper. Margin- RSI (14)50.36 Volatility6.44% 5.91%
OptionableYes Debt/Eq0.00 EPS Q/Q38.40% Profit Margin- Rel Volume0.48 Prev Close5.08
ShortableYes LT Debt/Eq0.00 EarningsMay 06 BMO Payout- Avg Volume204.76K Price5.25
Recom1.60 SMA201.62% SMA50-0.06% SMA200-8.80% Volume83,628 Change3.32%
Mar-08-21Initiated BTIG Research Buy $26
Sep-18-20Initiated William Blair Outperform
Dec-10-19Initiated Cantor Fitzgerald Overweight
Dec-02-19Upgrade Robert W. Baird Neutral → Outperform
May-13-19Initiated Piper Jaffray Overweight $10
Apr-09-19Initiated Wedbush Outperform $14
May-18-21 07:00AM  
May-06-21 11:05AM  
Apr-28-21 01:20AM  
Apr-27-21 07:00AM  
Mar-16-21 07:00AM  
Mar-12-21 07:00AM  
Mar-08-21 07:00AM  
Mar-02-21 07:00AM  
Feb-16-21 07:00AM  
Feb-14-21 11:23PM  
Jan-04-21 04:05PM  
Dec-31-20 07:00PM  
Dec-07-20 09:37PM  
Nov-19-20 07:00AM  
Nov-16-20 11:19PM  
Nov-10-20 04:05PM  
Nov-05-20 04:05PM  
Sep-17-20 07:00AM  
Sep-15-20 07:00AM  
Sep-08-20 07:00AM  
Aug-27-20 07:00AM  
Aug-13-20 03:30PM  
Aug-03-20 04:01PM  
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-03-20 01:11PM  
Jul-01-20 08:12AM  
Jun-30-20 04:05PM  
Jun-24-20 05:45PM  
Jun-17-20 05:50PM  
Jun-12-20 12:04PM  
May-12-20 08:00AM  
May-06-20 04:05PM  
May-05-20 05:45PM  
Apr-30-20 08:00AM  
Apr-27-20 05:45PM  
Apr-22-20 07:10AM  
Apr-20-20 09:06AM  
Apr-16-20 10:40AM  
Apr-15-20 08:45AM  
Apr-09-20 07:08AM  
Mar-30-20 08:00AM  
Mar-27-20 08:00AM  
Mar-24-20 08:00AM  
Feb-25-20 04:07PM  
Feb-18-20 08:00AM  
Jan-13-20 08:00AM  
Jan-10-20 07:13AM  
Jan-09-20 04:05PM  
Jan-02-20 08:34AM  
Dec-23-19 07:57PM  
Dec-20-19 08:00AM  
Dec-02-19 08:00AM  
Nov-29-19 08:51AM  
Nov-27-19 08:30AM  
Nov-26-19 05:14PM  
Nov-20-19 04:26PM  
Nov-12-19 08:00AM  
Nov-08-19 01:11PM  
Nov-07-19 04:05PM  
Nov-03-19 07:41AM  
Oct-18-19 08:00AM  
Sep-27-19 10:15AM  
Sep-19-19 08:13AM  
Sep-18-19 08:00AM  
Aug-08-19 04:15PM  
Aug-07-19 08:55PM  
Jul-31-19 03:16PM  
Jul-08-19 07:05AM  
May-08-19 06:35PM  
Apr-25-19 02:26PM  
Mar-19-19 07:05AM  
Mar-15-19 07:48AM  
Mar-11-19 02:14PM  
Mar-08-19 04:05PM  
Mar-07-19 04:04PM  
Mar-05-19 04:05PM  
Feb-28-19 04:10PM  
Feb-19-19 07:00AM  
Feb-14-19 07:00AM  
Jan-29-19 07:00AM  
Dec-11-18 08:05AM  
Nov-26-18 07:00AM  
Nov-13-18 07:00AM  
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Giaccia AmatoDirectorMar 19Option Exercise0.0612,083725953,963Mar 22 07:13 PM
Shah VinayChief Financial OfficerDec 04Buy5.768,00046,080189,842Dec 07 08:05 PM
McIntyre Gail FrancesCEO and PresidentDec 04Buy5.778,00046,16010,137Dec 07 08:00 PM